ArticleWorld journal of surgical oncology2026
LMNTD2-AS1 promotes esophageal squamous cell carcinoma progression by sponging miR-449b-5p to upregulate MYCN.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) remains a significant part of the global health burden, increasing the need to make its molecular basis clear in regard to therapeutic development. This study focuses on the long non-coding RNA LMNTD2-AS1 and its regulatory network in ESCC.
methodsThe expression level of LMNTD2-AS1 in clinical specimens and selected cell lines was quantified using quantitative RT‑PCR (qRT‑PCR). To assess its impact on malignant phenotypes, functional experiments including CCK‑8, Transwell, and flow cytometry‑based apoptosis assays were conducted. Subsequently, bioinformatic analyses combined with dual‑luciferase reporter assays were employed to validate the existence of a regulatory axis involving LMNTD2‑AS1, miR‑449b‑5p, and MYCN.
resultThis study revealed that LMNTD2-AS1 was significantly upregulated in ESCC tissues and cellular models. Downregulation of LMNTD2-AS1 expression decreased the rates of cell vitality and invasion while increasing apoptosis. LMNTD2-AS1 acted as a ceRNA and directly interacted with miR-449b-5p, resulting in the derepression of MYCN. Rescue assays confirmed that miR-449b-5p inhibition rescues the anti-tumor effects caused by LMNTD2-AS1 reduction. Reducing MYCN expression negated the cancer-promoting effects of inhibitory miR-449b-5p.
conclusionIn conclusion, this preliminary study demonstrates that LMNTD2-AS1 promotes ESCC progression via the miR-449b-5p/MYCN axis. By elucidating this network and its downstream signaling, we provide a mechanistic framework for ESCC pathogenesis. While broader clinical and in vivo validation is required, this axis represents a promising target for therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.